Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol APOA1 contributors: mct/npt - updated : 08-02-2019
HGNC name apolipoprotein A-I
HGNC id 600
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
4 - 897 - 267 - -
EXPRESSION
Type restricted
constitutive of
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Digestiveliver   highly
Endocrinepancreas   moderately
Lymphoid/Immunespleen   highly
 thymus   moderately
Reproductivemale systemseminal vesicles  moderately
Visualeyeanterior segmentcornea  
cell lineage
cell lines
fluid/secretion plasma
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
isoforms Precursor secreted as a proprotein and then cleaved by an uncharacterized metalloproteinase
HOMOLOGY
interspecies homolog to murine Apoa1 (65.91 pc)
Homologene
FAMILY
  • apolipoprotein A1/A4/E family
  • CATEGORY regulatory , transport carrier
    SUBCELLULAR LOCALIZATION extracellular
        intracellular
    intracellular,cytoplasm,organelle,membrane
    intracellular,cytoplasm,organelle,endoplasmic reticulum ,rough,smooth
    basic FUNCTION
  • involved in the reverse transport of cholesterol from tissues to liver
  • both APOM and APOA1 mRNA may considered as independent risk factors for macrosomia
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling sensory transduction/vision
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • ABCA1 mediates unfolding the N terminus of APOA1 on the cell surface, followed by lipidation of APOA1 and release of nascent HDL
  • ADRB3 might exert an anti-atherosclerotic effect by upregulating hepatic APOA1 expression and promoting the cholesterol reverse transport process
  • cell & other
    REGULATION
    Other cleaved by BMP1 (cleaves human proapolipoprotein A1 and regulates its activation for lipid binding) (Chau 2007)
    ASSOCIATED DISORDERS
    corresponding disease(s) NNHA , CCLD
    Susceptibility
  • to premature atherosclerosis and to low HDL-cholesterol
  • to premature coronary artery disease
  • Variant & Polymorphism other
  • deletion in exon 3 causing a frameshift and heterozygosity for a nucleotide substitution in exon 4 (T>G, L141R) increasing the risk of low HDL-cholesterol
  • mutation L178P leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
  • Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS